William Barchuk

Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels*

Edward A. Panacek, John C. Marshall, Timothy E. Albertson et al. · Critical Care Medicine · 2004 · 384 citations

Veterinary Medicine, Immunology, Pharmacotherapy +16

Adequacy of Early Empiric Antibiotic Treatment and Survival in Severe Sepsis: Experience from the MONARCS Trial

Rodger D. MacArthur, Mark Miller, Timothy Albertson et al. · Clinical Infectious Diseases · 2004 · 273 citations

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +16

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Atul Deodhar, Alice B. Gottlieb, Wolf‐­Henning Boehncke et al. · The Lancet · 2018 · 184 citations

Medicine, Clinical Sciences, Pharmacotherapy +7

A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-α antibody afelimomab in patients with sepsis syndrome

James J. Gallagher, Charles J. Fisher, Bruce W. Sherman et al. · Intensive Care Medicine · 2001 · 59 citations

Veterinary Medicine, Immunology, Pharmacokinetics +16

Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial)

Walter P. Maksymowych, Mikkel Østergaard, Robert Landewé et al. · Lara D. Veeken · 2021 · 37 citations · Full text

Medicine, Clinical Sciences, Radiology +16